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Abstract
Increased risk of acute myeloid leukemia/myelodysplastic syndromes following treatment has been reported in multiple myeloma, but whether dysplastic features are already present at diagnosis remains to be investigated.
Using multiparameter flow cytometry, we analyzed the distribution and phenotype of bone marrow hematopoietic cells from 47 multiple myeloma patients (15 symptomatic and 32 high-risk smoldering). From the 32 smoldering myeloma patients, 18 were studied at baseline and 22 after nine cycles of Lenalidomide/Dexamethasone treatment following the QUIREDEX trial (including eight from baseline). Phenotypic alterations of bone marrow cells of 7 (47%) symptomatic and 6 (33%) smoldering myeloma patients were detected at baseline, with no differences regarding the frequency and extent of phenotypic alterations between symptomatic versus smoldering cases. Likewise, no differences were noted between smoldering myeloma patients studied at baseline versus after Lenalidomide/Dexamethasone treatment. Our results suggest that phenotypic alterations of bone marrow hematopoietic cells are often present in newly diagnosed symptomatic and smoldering multiple myeloma patients.
QUIREDEX trial (NCT00480363)
Introduction
The association of alkylators with secondary hematological malignancies including myelodysplastic syndromes (MDS) is well recognized in multiple myeloma (MM);(1-5) by contrast, the potential association with lenalidomide only recently emerged,(6-8) raising concern among physicians and patients.
However, it remains to be determined whether dysplastic features are already present at diagnosis. In fact, it has been recently reported that not only MM, but also MGUS patients have a higher risk of AML/MDS development than agematched controls. (9) Multiparameter flow cytometry (MFC) immunophenotyping is currently considered a sensitive adjuvant test in the screening of MDS.(10, 11) Herein, we report a comprehensive analysis of the distribution and immunophenotypic profile of bone marrow (BM) hematopoietic cells in newly diagnosed symptomatic MM and high-risk smoldering MM (SMM). In addition, the BM of high-risk SMM cases after nine courses of lenalidomide plus dexamethasone (Len/Dex) was also analyzed.
Design and methods
A total of 47 myeloma (15 symptomatic and 32 SMM) patients were studied, all diagnosed according to the International Myeloma Working normal/reactive BM samples) were considered as altered. Accordingly, patients were classified as having "isolated alterations" (one alteration in one or more cell lineages) and "multiple alterations" (more than one alteration in one or more cell lineages). Patients with normal phenotypic profiles were categorized as "no alterations". The severity of the alterations was evaluated using a previously reported immunophenotypic score (10, 11) that gives 1 or 2 points to each phenotypic parameter that has a deviation from normal reference values between 3-4SD or >4SD, respectively (Supplementary methods). The overall score for each sample was determined by the sum of all partial scores. In SMM patients included in the QUIREDEX trial, central morphological review of BM slides specifically for blast count and dysplasia was performed in 17 of 18 cases at diagnosis and in 12 cases after the 9 induction cycles of Len/Dex.
Response rates in the former group were as follows: 19% achieved (stringent 5 and conventional) complete remission, 10% very good partial response, 57% partial response, and 14% remained with stable disease.
According to standard criteria, FISH analyses (and not conventional karyotyping) were performed on immunomagnetically enriched plasma cells.
Group differences were compared using the χ 2 and Mann-Whitney U tests for categorical and continuous variables, respectively (SPSS 18.0, Chicago, IL).
Results and Discussion
The survival of MM has significantly increased in the last decade (13-15), but this prolongation has also alerted to the potential risk of secondary MDS associated with some drugs/regimens, particularly alkylating-based schemes(1, 2) and more recently lenalidomide treatment.(6-8) In turn, a predisposition to an overt MDS was recently observed in the overall MM (and MGUS) population. (9) However, a comprehensive screening of dysplastic features has not been performed in newly diagnosed myeloma patients. In the present study, "multiple phenotypic alterations" similar to those observed in MDS patients were found at diagnosis in 2 of 15 (13%) symptomatic MM but not in SMM patients (Table 1) .
Therefore, the incidence of dysplastic features reported in MM after HDT/ASCT (1-13%)(1-4, 16, 17) could have been overestimated since some of these may already be present at baseline.(18) Noteworthy, up to 20% of all myeloma patients showed an immunophenotypic score that is found only in MDS but not in normal/reactive BM samples (Supplementary Table 1 ).
In addition to the aforementioned "multiple alterations", "isolated phenotypic alterations" at baseline were noted in 34% of symptomatic MM (5 of 6 15) and 33% of high-risk SMM (6 of 18) cases ( (24) we should not discount the alternative possibility: a reduction in the number of phenotypic alterations after treatment. Overall, no significant differences were noted between SMM patients after treatment and the baseline cohort with respect to the frequency and severity of the alterations detected (as evaluated by the immunophenotypic score), except for a trend towards increased frequency of phenotypically altered erythroblasts (p=.08) ( Tables 1-2 and Supplementary   Table 1) . Similarly, no differences were noted in the frequency of cases with mild morphological alterations before and after Len/Dex treatment (25% vs.
18%; p=.6).
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Supplementary Methods
Immunophenotypic studies and flow cytometric score Whole BM samples (2 x 10 6 cells in 100 µl/test) were stained for cell surface markers using a stain-lyse-and-then-wash direct immunofluorescence technique, while intracellular stainings (nuclear (n) and cytoplasmic (Cy)) were figure 1C . (N = 83) in each BM sample, a score of 0, 0.5, 1 or 2 was given when the values were, respectively, within ± 2 SD, ± 2-3 SD, ± 3-4 SD, ± >4 SD of the mean values found for that parameter among the normal BM samples analyzed. -/lo cells) and, e) basophil and pDC maturation (percentage of cells and expression of CD123). No significant differences were found between symptomatic and smoldering MM patients at diagnosis, or between smoldering MM patients before and after treatment.
Immunophenotypic variables studied
Supplementary Table 2. Distribution of hematopoietic bone marrow (BM) cell populations in patients with symptomatic multiple myeloma (MM) and smoldering multiple myeloma (SMM) at diagnosis, and SMM cases after induction therapy with nine courses of lenalidomide plus dexamethasone (Len/Dex). 
